Astroglial dysregulation and gliotransmitter imbalance in schizophrenia.

Neuroinflammation as a Pharmacological Target in Psychiatric Disorders.

A comprehensive understanding of neuroinflammatory mechanisms may provide new opportunities for developing targeted therapeutic interventions and improving clinical outcomes in psychiatric disorders, including patient stratification and enable precision psychiatry.

Microglial advances in psychiatric disorders.

Emerging therapeutic strategies targeting microglia were discussed, including anti-inflammatory approaches, functional reprogramming, neuromodulation techniques, and microglial replacement or niche engineering, indicating a paradigm shift from indiscriminate microglia inhibition to the precise modulation of specific fu...

Astrocytes orchestrate neuroprotection and pathogenesis via bidirectional neuronal interactions in Parkinson’s disease

554. Kynurenic acid and promotion of activity-dependent synapse elimination in schizophrenia

These findings link KYNA to excessive, activity-dependent synaptic elimination in human cellular models of schizophrenia and show that its dynamics are sensitive to immune signaling.

Emerging Advances in Neuropharmacology: Novel Therapeutic Targets for Neurodegenerative Disorders

Neurodegenerative diseases are a heterogeneous group of chronic and progressive disorders, which are characterized by selective neuronal destruction, synaptic malfunction and progressive cognitive and locomotor dysfunction. The major ones are Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lat...

Altered glutamatergic neurotransmission in the development and maintenance of PTSD.

Post-traumatic stress disorder (PTSD) is a multifactorial neuropsychiatric condition characterized by persistent disturbances in fear processing, emotional regulation, and memory. Increasing evidence indicates that dysregulation of glutamatergic neurotransmission plays a crucial role in both the development and persist...